Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our multi-cancer early detection test (“Galleri”) can screen for many types of cancer, accurately predicting the specific organ or tissue type where the cancer signal originated (the “Cancer Signal of Origin”, or “CSO”), with high positive predictive values (“PPV”) and low false positive rates, all from a simple blood draw.
In the company’s own words · 10-K filed Mar 12, 2026 · SEC EDGAR
Business segments
Q2 2026 · $42.6MThe company’s own SEC segment disclosure.
- United States$41.4M97%
- Non Us$1.2M3%
GRAIL, Inc. (GRAL) reported revenue of $45M in Q2 2026 (quarter ended Jun 30, 2026), up 26% from the same quarter a year earlier. That came with net loss of $110M. For the full year FY2025, revenue was $147M (+17% year on year) and net income −$408M. Its largest region in Q2 2026 was United States at $41M, 97% of the disclosed total, well ahead of Non Us at 2.8%.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #6 of 17 by Smart Score